ARQT · Arcutis Biotherapeutics, Inc. · Webcasts, Transcripts & Audio
$28.26
+0.73 (+2.65%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$3.57B
Shares
126.46M
Volume · Nov 13
858.23K
Avg daily vol (3M)
2.62M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Arcutis Biotherapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Arcutis Biotherapeutics, Inc. (ARQT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-10
Arcutis Biotherapeutics, Inc. (ARQT) November 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript
Confident tone
Awareness and commercial expansion
ARQ-234 pipeline development
Core Zareev sales and demand growth
Revenue
$143.92M
▲ 45.1% YoY Diluted EPS
$0.06
▲ 0% YoY Gross margin
91.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Arcutis Biotherapeutics, Inc. (ARQT) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
Confident tone
Pediatric label expansion
Primary care and pediatric sales force
Patient access initiatives
Revenue
$129.86M
▲ 59.3% YoY Diluted EPS
$0.11
Gross margin
91.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Arcutis Biotherapeutics, Inc. (ARQT) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Confident tone
Atopic dermatitis pediatric sNDA (3 to 24 months)
Pipeline expansion: vitiligo and HS Phase 2 POC
Zoryve net product revenue growth
Revenue
$105.40M
▲ 60.1% YoY Diluted EPS
$-0.09
Gross margin
90.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-14
Arcutis Biotherapeutics, Inc. (ARQT) April 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-02
Arcutis Biotherapeutics, Inc. (ARQT) March 2, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-25
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Confident tone
FDA label expansions and submissions
Infant atopic dermatitis (INTEGUMENT trial)
Zareve (topical roflumilast) commercial growth
Revenue
$129.50M*
▲ 81.5% YoY Gross margin
91.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2025 Earnings Call Transcript
Confident tone
ZORYVE commercial momentum
Pipeline and ARQ-234 biologic
Life cycle management and label expansions
Revenue
$99.22M
▲ 121.7% YoY Diluted EPS
$0.06
Gross margin
91.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript
Confident tone
Medicare/Medicaid access and reimbursement
Pipeline expansion and label growth
Seasonality and quarterly guidance
Revenue
$81.50M
▲ 164.1% YoY Diluted EPS
$-0.13
Gross margin
90.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript
Confident tone
ZORYVE commercial performance and growth
Market expansion from topical steroids
Upcoming regulatory catalysts and label expansion
Revenue
$65.85M
▲ 32.8% YoY Diluted EPS
$-0.20
Gross margin
86.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript
Confident tone
ZORYVE product growth and sales momentum
Foam vs. cream cannibalization concerns
Label expansion and pipeline indications
Revenue
$71.36M*
▲ 427.6% YoY Gross margin
90.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript
Confident tone
Label expansion and pipeline
Kowa co-promotion partnership
Government payer access (Medicare/Medicaid)
Revenue
$44.76M
▲ 17.4% YoY Diluted EPS
$-0.33
Gross margin
87.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript
Confident tone
ZORYVE cream (psoriasis) launch
ZORYVE foam (seb derm) launch
Atopic dermatitis launch
Revenue
$30.86M
▲ 494.6% YoY Diluted EPS
$-0.42
Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript
Confident tone
Atopic dermatitis regulatory and pipeline milestone
ZORYVE cream psoriasis launch momentum
ZORYVE foam seb derm launch
Revenue
$49.57M
▲ 1682.4% YoY Diluted EPS
$-0.32
Gross margin
93.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript
Confident tone
ZORYVE foam seborrheic dermatitis launch
ZORYVE cream psoriasis launch momentum
Payer access and Medicare/Medicaid expansion
Revenue
$13.53M*
▲ 356.8% YoY Gross margin
83.4%
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-03
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript
Revenue
$38.11M
▲ 5156.4% YoY Diluted EPS
$-0.73
Gross margin
96.9%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Call Transcript
Revenue
$5.19M
Diluted EPS
$-1.16
Gross margin
85.0%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2023 Earnings Call Transcript
Revenue
$2.78M
Diluted EPS
$-1.31
Gross margin
71.8%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2022 Earnings Call Transcript
Revenue
$2.96M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2022 Earnings Call Transcript
Revenue
$725,000
Diluted EPS
$-1.89
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 webcasts
Key facts
CIK
1787306
CUSIP
03969K108
13F (30d)
222 filings
200 filers
Visit website
Investor relations